Introduction
In an attempt to decrease transplant-related toxicity, reducedintensity conditioning regimens (RIC) are increasingly being used prior to allogeneic stem cell transplantation (allo-SCT). RIC-allo-SCT has been shown to be able to mediate a powerful graft-versus-tumor effect in patients with hematological and nonhematological malignancies. [1] [2] [3] The rapidly increasing use of RIC-allo-SCT emphasizes the need for clinical research aimed at identifying variables predictive of RIC-allo-SCT outcome. Dendritic cells (DCs) are crucial in the induction of immune responses. Among DC subsets, the reconstitution of the natural type I-interferon-producing plasmacytoid DCs (PDC) has been proposed to play a major role in establishing immune competence, given the capacity of PDCs to efficiently expand either specific cytotoxic T-lymphocytes 4 or to promote regulatory T cells, contributing to an impaired immune response. 5, 6 Therefore, we investigated the impact of circulating PDCs measured at the third month after RIC-allo-SCT, in 54 patients who received an RIC-allo-SCT from an HLA-identical sibling, in order to determine whether this could provide a convenient indicator for long-term outcome.
Patients and methods

Study design
In all, 54 consecutive patients treated with RIC-allo-SCT in different trials in a single center (Institut Paoli-Calmettes) with a minimal follow-up of 3 months were included in this analysis. Written informed consent was obtained from each patient and donor. The studies were approved by the local ethical committee and performed according to institutional guidelines. The eligibility criteria for RIC-allo-SCT have been detailed elsewhere. 2, 7 Patients, donors and grafts characteristics are summarized in Table 1 .
Transplant procedures
The RIC regimen included either fludarabine, oral busulfan and various doses of antithymocyte globulin (thymoglobuline; SangStat, Lyon, France), 2 or fludarabine and low-dose total body irradiation. 8 Supportive care has been previously reported and was similar during the whole study period. 7 Graft-versushost-disease (GVHD) prophylaxis was carried out with cyclosporin A (CSA) alone or with CSA and mycophenolate mofetil. 8, 9 The majority of patients (87%) received a peripheral blood stem cell allograft mobilized with G-CSF (10 mg/kg/day) for 5 days. Immunophenotyping of the allograft cellular content was performed using standard techniques.
PDCs analysis
PDCs analysis was performed for all 54 patients at a median of 92 days after allo-SCT (range, 74-133). Blood DCs were identified by three-color staining performed on PBMCs using the following monoclonal antibodies: ZM3.8-PC5 (mAb against ILT3, an immunoglobulin-like transcript recently used to isolate DCs from the blood, mouse IgG1), 10 BU15-phycoerythrin (mAb against CD11c) and fluorescein isothiocyanate-labeled mAbs against lineage markers CD3, CD14, CD16, CD19 and CD56 (Beckman-Coulter, Marseille, France). Cells that did not label with these lineage markers were designated as lineage negative (linÀ). PDCs were defined with the phenotype of linÀ/CD11cÀ/ ILT3 þ . [11] [12] [13] This reproducible technique has been routinely used in our laboratory for more than 5 years. [13] [14] [15] [16] [17] [18] Cells were analyzed on a FACSCalibur cytometer using CellQuest software (Becton-Dickinson, San Jose, CA, USA). Other cell subsets frequencies (total white blood cells (WBCs), neutrophils, lymphocytes and monocytes) were obtained for all patients from a standard automated counter. The IFN-a secretion assay after viral stimulation was performed as described previously. 17, 19 Briefly, 10 5 cells were plated in triplicate in 96-well round-bottomed plates and stimulated with herpes simplex virus (kind gift of Dr C Zandotti, Hô pital La Timone, Marseille, France) for 48 h. Supernatants were tested for their IFN-a content by ELISA (Bender MedSystems, Vienna, Austria).
Clinical outcomes and statistical methods
Acute and chronic GVHD (aGVHD, cGVHD) were evaluated according to standard criteria. 20 Upon diagnosis of grade II-IV aGVHD, all patients were primarily treated with CSA and methylprednisolone (2 mg/kg/day). Data were computed using s.e.m. software (SILEX, Mirefleurs, France). The Mann-Whitney test was used for comparison of continuous variables. Categorical variables were compared using the w 2 test. The probability of developing aGVHD was depicted by calculating the cumulative incidence. Cumulative incidence estimates were Table 1 Demographic and graft characteristics of the 'low' vs 'high' PDC recovery groups at 3 months after transplantation also used to measure the probability of relapse or progression and transplant-related mortality. Probabilities of overall and progression-free survival (OS, PFS) were estimated from the time of transplantation using the Kaplan-Meier product-limit estimates. Differences between groups were tested using the logrank test. A multiple logistic regression with backward stepwise model selection was used to depict predictive factors for PDCs recovery at 3 months after allo-SCT. The association of time to death with the PDC count and other relevant variables was evaluated in a multivariate analysis with the use of Cox's proportional-hazard regression model.
Results and discussion
The median absolute count of PDCs measured at 3 months after RIC-allo-SCT was 0.725/ml (range, 0-23.2). Thus, for the purpose of allocating patients to 'low' vs a 'high' PDC recovery group, the median value of 0.725/ml was used (Figure 1a) . Baseline demographic and graft characteristics for both groups are shown in Table 1 . Overall, the cumulative incidence of grade II-IV aGVHD (median onset, 34 days) was 39% (95% CI, 26-52%), with this being significantly higher in the 'low' PDC recovery group at 3 months (59 vs 19%; P ¼ 0.005; Table 2 ). In a multiple logistic regression analysis including all relevant parameters (demographic and graft characteristics, RIC regimens, CMV infections and aGVHD), only the absence of clinically significant grade II-IV aGVHD was associated with an improved PDC recovery at 3 months (P ¼ 0.003; OR ¼ 6.4; 95% CI, 1.9-22). Being the major type I IFN-secreting cells, we also investigated whether PDCs recovered after allo-SCT are functional in response to viral stimulation. Patients experiencing grade 0-I aGVHD could secrete significantly higher amounts of IFN-a as compared to patients with grade II-IV aGVHD (mean, 91 vs 0 pg/ml respectively; P ¼ 0.002; Figure 1b) , likely highlighting the deleterious impact of corticosteroids therapy on PDC function as described previously. 21, 22 As previously shown in the myeloablative allo-SCT setting, the CD34 þ stem cell dose and other lymphoid subsets infused with the allograft did not correlate with PDC recovery after RICallo-SCT. 23 Patients with a 'low' PDC recovery had also significantly decreased lymphocyte, monocyte, but not neutrophil counts in comparison with the 'high' PDC recovery group Table 2 Transplant-related events and outcome of the 'low' vs 'high' PDC recovery groups at 3 months after transplantation Nonrelapse mortality according to the 'low' vs 'high' PDCs recovery groups determined at the third month after RIC-allo-SCT. Dashed lines, 'low' PDC recovery group; solid lines, 'high' PDC recovery group.
PDC and outcome after RIC-allo-SCT M Mohty et al (P ¼ 0.004 and 0.025, respectively; Table 2 ). Patients from the 'low' and 'high' PDC recovery groups had a comparable rate of cGVHD (P ¼ NS). Deaths from progression or relapse were comparable between both groups (P ¼ NS). However, nonrelapse mortality was significantly higher in the 'low' PDC group, since six patients in the 'low' PDC recovery group died of refractory cGVHD (n ¼ 3) or infection (n ¼ 3) as compared to none of the patients in the 'high' PDC recovery group (P ¼ 0.03; Figure 2 ). Interestingly, the overall incidence of late infections (viral, fungal and bacterial) was significantly higher in the 'low' PDC recovery group as compared to the 'high' PDC recovery group (59 vs 19%; P ¼ 0.002), further illustrating the importance of PDCs in anti-infectious immune responses. 24 With a median follow-up of 11 (range, 4.5-45) months for the 37 surviving patients (23 complete remissions, six partial remissions, two stable and six progressive diseases), the Kaplan-Meier estimate of OS at 3 years is 51% (95% CI, 32-64%; Figure 3a) . PFS was not significantly different between the 'low' and 'high' PDC recovery groups (P ¼ NS; Figure 3b ). However, given the significantly increased nonrelapse mortality in the 'low' PDC recovery group, patients from the 'high' PDC recovery group had a significantly better OS (P ¼ 0.03; Figure 3c ). After controlling for demographic, graft and transplant characteristics, aGVHD, monocytes and lymphocytes counts, in the multivariate analysis, only a 'high' PDC count measured at 3 months after allo-SCT was significantly predictive of an improved OS and a decreased risk of death (P ¼ 0.04; RR ¼ 0.34; 95% CI, 0.12-0.96).
Recently, an ever-growing body of data highlighted the role of PDCs after allo-SCT or solid organ transplantation. 21, 22, [25] [26] [27] [28] The results from our study suggest that quantification of PDCs at 3 months after RIC-allo-SCT (widely used date for allo-SCT patient assessment) 29 may be a simple but major indicator for long-term outcome, especially transplant-related mortality and OS. Interestingly, in patients receiving a myeloablative standard allo-SCT, Reddy et al 27 could show recently that a 'low' DC recovery (including PDCs) at the time of engraftment is associated with a worsened early outcome. However, the latter study could not determine whether this is clinically relevant for RIC-allo-SCT patients. 27 In our study, the PDC count did not correlate with the risk of disease progression or relapse. This might be explained by the predominance in our series of high-risk patients with a high tumor burden (82%), a group where complex PDC-tumor interactions 30 might preclude exact evaluation of the impact of one subset of DCs on antitumor immunity. In addition to quantification, functional studies are warranted to decipher the role of PDCs in antitumor immunity that is still under considerable discussion. 17, 30, 31 Nonetheless, although blood PDCs might not completely reflect the status of PDCs in other tissues, the increased mortality rate from infections and refractory GVHD in patients with low PDC recovery further establishes the crucial role of PDCs for both efficient immune defenses, 4 and maintenance of tolerance, 5, 6, 32, 33 that would temper the severity of cGVHD. In this context, another determinant for GVHD development and severity might be PDC chimerism. 34 However, we and others have previously shown that selectively sorted circulating PDCs recovered after RIC-allo-SCT are of exclusive donor origin. 14, 35 Although the group of patients analyzed in this study was rather heterogeneous as for diagnoses and transplant characteristics, precluding establishing the definitive role and impact of the PDC subset after allogeneic transplantation, one must admit that the role and impact of rare immune effector cells would tend to be more evident in truly RIC and less toxic regimens. Prospective studies focussing on PDCs, but also other DC subsets (myeloid CD11c þ and CD16 þ DC subsets) are still needed in homogeneous groups of patients. Nonetheless, from the results of this study, we can reasonably envision that monitoring of PDCs may be useful for patients' management (closer surveillance, infection prophylaxis, etc), and may have a significant impact on the probability of a favorable outcome in the context of RIC-allo-SCT. PDC and outcome after RIC-allo-SCT M Mohty et al
